Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company's broad product portfolio and application expertise are used in scientific investigations into biological processes and molecular diagnostics, aiding in drug discovery and clinical tests. Bio-Techne operates through two segments: Protein Sciences and Diagnostics and Genomics.

• Employees: Approximately 3,100 (as of June 30, 2024)
• Geographic Footprint: Offices in North America, Europe, and Asia
• Headquarters: Minneapolis, Minnesota
• Founded: 1976
• Revenue: $1.2 billion (FY2024)
• Trading Symbol: TECH (NASDAQ)

• CEO: Kim Kelderman (since February 1, 2024)
• CFO: James Hippel (since April 1, 2014)
• President, Protein Sciences: William Geist (since January 3, 2022)
• President, Diagnostics and Genomics: Matthew McManus (since January 8, 2024)
• Senior Vice President, General Counsel & Corp. Secretary: Shane Bohnen (since March 3, 2023)

Key executives have diverse backgrounds in life sciences and finance.

• Annual Revenue: $1.2 billion (FY2024)
• Net Income: Not explicitly stated, but net earnings attributable to Bio-Techne was $168.1 million (FY2024)
• Market Cap: $12.1 billion (as of December 31, 2023)
• Total Assets: $2.7 billion (as of June 30, 2024)
• Employees: Approximately 3,100 (as of June 30, 2024)
• Key Financial Highlights: Organic revenue growth of 1% (FY2024), with acquisitions having a favorable impact of 1%.

Bio-Techne offers a wide range of products and services, including:

• Protein Sciences: High-quality biological reagents, proteomic analytical tools, and automated western blot and ELISA workflows.
• Diagnostics and Genomics: Diagnostic products, controls, calibrators, diagnostic assays, exosome-based molecular diagnostic assays, and tissue-based in-situ hybridization assays.

The company operates through two main segments:

• Protein Sciences: Representing approximately 72% of net sales in fiscal 2024.
• Diagnostics and Genomics: Representing approximately 28% of net revenues in fiscal 2024.

Bio-Techne's strategy focuses on:

• Growing and leveraging core business through collaborations and internal talent.
• Capitalizing on high potential markets by leveraging a strong balance sheet.
• Expanding markets through innovation and acquisitions.
• Delivering a best-in-class customer experience.
• Developing people through a transformative culture.

Bio-Techne operates in the life sciences, diagnostics, and bioprocessing industries. Key aspects of the competitive landscape include:

• Market Position: Difficult to determine exact competitive position due to the range of products and services offered.
• Key Competitors: A wide variety of competitors, including large global companies and smaller niche competitors.
• Industry Trends: Constant pressures and changes in healthcare and life sciences industries to reduce costs and increase predictability.

• Economic and Industry Risks: Global economic conditions, international political factors, and changes in healthcare and life sciences industries.
• Acquisition and Investment Risks: Inability to complete acquisitions at historical rates, difficulties in integrating acquired businesses, and potential impairment of goodwill.
• Strategic and Operational Risks: Dependence on recruiting and retaining qualified personnel, timely development of new products, intense competition, and disruptions in information technology systems and supply chains.
• Intellectual Property Risks: Dependence on maintaining intellectual property rights and potential disputes over proprietary rights.
• Financial and Tax Risks: Potential impact of additional debt, foreign currency exchange rates, and changes in tax laws.
• Legal, Regulatory, Compliance and Reputational Risks: Extensive regulation, changes in trade policies, and potential issues related to compliance with privacy and security laws.